My professional journey across bench science, clinical medicine, and regulatory science at FDA, has provided a uniquely broad background in drug development. As a clinical fellow and then an investigator and attending physician at NIH, I developed a program at the intersection of infectious diseases, autoimmunity, and oncology. I became a leading international authority in diagnosing and managing patients with acquired, genetic, and malignancy-associated immunodeficiencies related to endogenous production of high-titer, neutralizing anticytokine autoantibodies. Subsequently, I brought my scientific and clinical experience to the FDA, first as a clinical reviewer, then progressing quickly in management as Senior Advisor for Clinical Review and Office Lead for Biomarkers. In 2020, I joined Altimmune and have been clinical development lead for all programs in obesity, metabolic, and liver disease. While at Altimmune, I have built a diverse team encompassing clinical development, pharmacovigilance, medical affairs, and medical monitoring to advance programs from First-in-Human through Phase 2. I have established multiple scientific advisory boards, managing internationally recognized experts across the fields of obesity, cardiometabolic, hepatology, renal, and body composition. I strive to bring vision and pragmatism to execute evidence-based, creative, and ambitious clinical development programs through hands-on engagement, team-building, and cross-disciplinary collaboration.